Get the Stockscreener App
8.50
2.53%
0.21
After Hours:
8.51
0.010
+0.12%
Imunon Inc stock is traded at $8.50, with a volume of 106.12K.
It is up +2.53% in the last 24 hours and down -27.46% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$8.29
Open:
$8.155
24h Volume:
106.12K
Relative Volume:
0.13
Market Cap:
$17.59M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-4.4974
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
+21.43%
1M Performance:
-27.46%
6M Performance:
-35.97%
1Y Performance:
-57.71%
1-Day Range:
$8.01
$8.6963
1-Week Range:
$7.1022
$9.18
52-Week Range:
$5.55
$47.40
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
8.50 | 17.59M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Stock (IMNN) Latest News
How volatile is Imunon Inc. stock compared to the marketFinancial News Data Feed With High Returns - jammulinksnews.com
Is Imunon Inc. stock overvalued or undervaluedExpert Picks Tips With High Returns - jammulinksnews.com
When is Imunon Inc. stock expected to show significant growthAdvanced Screener Growth Plan For Fast Growth - jammulinksnews.com
How does Imunon Inc. generate profit in a changing economyFinancial News Planner For Beginners - jammulinksnews.com
What are the latest earnings results for Imunon Inc.Smart Portfolio Growth Plan That Work - jammulinksnews.com
What catalysts could drive Imunon Inc. stock higher in 2025Stock Strategy Insights For Consistent Profits - jammulinksnews.com
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 - GlobeNewswire
Imunon stock surges after first patient dosed in Phase 3 ovarian cancer trial - Investing.com Nigeria
Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued - Stocktwits
Imunon announces first patient dosed in Phase 3 OVATION 3 study of IMNN-001 - TipRanks
First patient dosed in IMUNON’s phase 3 ovarian cancer trial By Investing.com - Investing.com India
First patient dosed in IMUNON’s phase 3 ovarian cancer trial - Investing.com Australia
IMUNON Advances Revolutionary Ovarian Cancer Treatment to Phase 3 After Strong Survival Data - Stock Titan
IMUNON to Hold Second Quarter 2025 Financial Results and - GlobeNewswire
IMUNON Earnings Call: Latest Phase 3 Data Coming for DNA-Based Ovarian Cancer Immunotherapy - Stock Titan
Order Book Volume Tilts Bullish on Imunon Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
Why Imunon Inc. stock attracts strong analyst attentionEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Should I hold or sell Imunon Inc. stock in 2025Pre Market Ideas For Beginners - jammulinksnews.com
Imunon Announces 15% Stock Dividend Approval - TipRanks
IMUNON's Strategic Repositioning: Reverse Split and Stock Dividend as Catalysts for Shareholder Value and Nasdaq Compliance - AInvest
IMUNON Announces Stock Dividend Boosting Shareholder Value - The Manila Times
IMUNON Rewards Shareholders with 15% Stock Dividend After Breakthrough Ovarian Cancer Trial Results - Stock Titan
How does Imunon Inc. compare to its industry peersMaximize gains with timely market signals - jammulinksnews.com
What is the dividend policy of Imunon Inc. stockMaximize gains with timely market signals - jammulinksnews.com
How strong is Imunon Inc. company’s balance sheetMaximize returns with data-driven strategies - jammulinksnews.com
Is Imunon Inc. a growth stock or a value stockAchieve consistent double-digit returns - jammulinksnews.com
Why is Imunon Inc. stock attracting strong analyst attentionBuild wealth with steady, reliable stocks - jammulinksnews.com
IMUNON announces reverse stock split - MSN
Imunon, Inc. Advances DNA Vaccine Study for COVID-19 Variants - TipRanks
What analysts say about Imunon Inc. stockMarket-leading capital gains - PrintWeekIndia
Imunon Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks
Is Imunon Inc. a good long term investmentDouble-digit growth - PrintWeekIndia
What drives Imunon Inc. stock priceFree Stock Index Interpretation - PrintWeekIndia
Celsion (IMNN) Trading Halted Due to Anticipated News Announcement | IMNN Stock News - GuruFocus
Imunon Inc. Stock Analysis and ForecastFree Stock Market Trend Analysis - Autocar Professional
IMUNON Announces Reverse Stock Split - GlobeNewswire
Imunon, Inc. Advances COVID-19 Vaccine Research with IMNN-101 Study Completion - TipRanks
Imunon announces 1-for-15 reverse split ratio - TipRanks
Imunon Plunges 16.67% on Failed Trial, Widening Losses - AInvest
IMUNON, Inc. Announces 1-for-15 Reverse Stock Split Effective July 25, 2025 - Quiver Quantitative
IMUNON announces 1-for-15 reverse stock split to maintain Nasdaq listing - Investing.com Nigeria
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):